Marie-Louise Fjallskog tapped as Faron's new chief medical officer
4th Jan 2022 16:10
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced the appointment of Marie-Louise Fjällskog as its chief medical officer on Tuesday, to be based in Boston, Massachusetts and effective immediately.
Read moreFaron Pharmaceuticals wins dispute with Rentschler at tribunal
9th Nov 2021 11:23
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Tuesday that the arbitration tribunal appointed by the Arbitration Institute of the Stockholm Chamber of Commerce (SCC) had ruled in its favour in its case against Rentschler Biopharma.
Read moreFaron doses first patient in Covid-19 treatment trial
25th Aug 2021 11:43
(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals announced on Wednesday that the first patient has been dosed in the phase 2 and 3 'HIBISCUS' trial, assessing 'Traumakine', or intravenous interferon beta-1a, as a first-line treatment for hospitalised Covid-19 patients.
Read moreNew research supports mode of action in Faron's 'MATINS' study
3rd Jun 2021 14:47
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced the publication of research supporting the immunotherapeutic blockade of 'Clever-1' to activate anti-tumour immune responses in advanced cancer patients on Thursday.
Read moreFaron Pharmaceuticals reports 'promising' data from drug study
17th May 2021 10:13
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced "promising" new data from its ongoing bexmarilimab 'MATINS' study on Monday, reporting combined headline data from 141 evaluable patients enrolled in the completed first part and the ongoing second part of the study.
Read moreFaron Pharmaceuticals signs US sublicence agreement
14th May 2021 11:18
(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has signed a sublicence agreement for the rights to United States patent US9,376,478, it announced on Friday, which currently extends to 2033.
Read moreFaron Pharmaceuticals gets Finnish state loan for manufacturing process
15th Jun 2020 12:44
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced plans to initiate a new "state-of-the-art" process for the manufacturing of 'interferon' (IFN) beta-1a on Monday.
Read moreFaron receives EIC grant for 'MATINS' study
11th Jun 2020 13:51
(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has been selected to receive a €2.5m (£2.24m) grant from the European Innovation Council's 'Accelerator' pilot scheme, it announced on Thursday, to progress the 'MATINS' study, and related business activities.
Read moreFaron Pharmaceuticals confirms publication of 'crucial' study
20th May 2020 10:37
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Wednesday that the results of its detailed analyses into the effects of glucocorticoids on intravenous interferon beta-1a activity, which arose following the 'INTEREST' trial in 2018, had been published in critical care journal Intensive Care Medicine.
Read moreFaron Pharmaceuticals inks manufacturing deal with AGC Biologics
5th May 2020 09:20
(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has selected contract development and manufacturing organisation AGC Biologics as the commercial-scale manufacturer of 'Clevegen', it announced on Tuesday.
Read moreFaron gets FDA tick from proposed design of next 'Traumakine' study
9th Mar 2020 10:26
(Sharecast News) - Faron Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has accepted its proposed protocol design for the next 'Traumakine' study in acute respiratory distress syndrome (ARDS) patients, following its protocol submission in February.
Read moreFaron Pharmaceuticals acquires rights to AOC3 inhibitors
2nd Mar 2020 10:08
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has acquired rights for the potential new use of AOC3 inhibitors covered by a recently filed patent application.
Read moreFaron Pharma requests arbitration over Traumakine manufacturing deal
30th Dec 2019 15:39
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that, further to the update on 'Traumakine' drug substance manufacturing on 2 October, it has carried out a detailed investigation into the circumstances around manufacturing arrangements.
Read moreFaron Pharmaceuticals upbeat on new data from 'MATINS' study
11th Dec 2019 13:42
(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced new data from 'MATINS'-trial patients on Wednesday, to be presented at the ESMO Immuno-Oncology Congress 2019 in Geneva.
Read moreFaron Pharmaceuticals positive on feedback from 'Clevegen' monitoring committee
9th Oct 2019 14:05
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced feedback from the 'MATINS' study data monitoring committee on Wednesday, from the ongoing dose escalation study from part 1 of the MATINS trial.
Read more